Advances in Ovarian Cancer: Using Genomics and Optimizing Maintenance Therapy
Access to Minimally Invasive Surgery for Advanced Ovarian Cancer Varies Widely by Facility
Real-World Data Show Bevacizumab Benefits Only High-Risk Patients With Epithelial Ovarian Cancer
ROSELLA Trial Offers New Insight Into Global Treatment Strategies for Ovarian Cancer: Brian Slomovitz, MD
Learnings From Key Clinical Trials in Ovarian Cancer
The Potential Impact of Investigational Therapies
Relacorilant Plus Nab-Paclitaxel Improves Outcomes in Platinum-Resistant Ovarian Cancer: Brian Slomovitz, MD
Ovarian, Breast Cancer Disparities Highlight Need for Better Screening: CK Wang, MD
Single-Agent Vs Combination Regimens
Approaching Treatment Sequencing In Heavily Pretreated Patients
The Use of PARP Inhibitors in Ovarian Cancer
Earlier Introduction of Antibody-Drug Conjugates
Racial Disparities in Ovarian Cancer Could Increase as Trends Point to Access Barriers: CK Wang, MD
Ovarian Cancer Outcomes Linked to Preoperative Immunonutritional Status